AGIO250117P35000
- 3.32
- -0.28-7.78%
Agios Pharmaceuticals Newsroom
How to Navigate the Stock and Bond Markets in 2025 -- Journal Report
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
The Best U.S. Value Stocks by Quant: AGIO, DLX, PPC
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight
The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Here's Why Agios Stock Plummeted More Than 20% on Monday
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Small U.S. Stocks Decrease; Agios Pharmaceuticals Posts Biggest Loss
Agios Pharmaceuticals Down Nearly 22%, on Pace for Record Percent Decrease -- Data Talk
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Agios Pharmaceuticals Analyst Ratings
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Agios Reports Results From Late-stage Study of Its Thalassemia Treatment
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $75
Express News | Agios Pharmaceuticals Inc : Scotiabank Raises Target Price to $75 From $53
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals